Introducing Miro Sciences Ltd - Presentation
Filed with ASX · · 18 pages · English
Summary by 6ix AI
It highlights the significant unmet need in the Crohn's disease market and the potential for StemSmart™ to address patients who have exhausted current treatment options. The presentation also discusses the company's manufacturing readiness and plans for clinical supply at scale.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Miro Sciences
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appointment of CFO
- Results of Annual General Meeting
- US FDA Provides Positive Feedback on Planned Phase 2 Trial
- Leading CRO Appointed for Phase 2 Crohn's Trial
Follow Miro Sciences into a list and get an email when it puts out news.
Follow Miro Sciences